510(k) Report

FDA product code · Pathology

System, Test, (Ihc), Tumor Marker, Monitoring, Bladder Cancer

NBKClass II21 CFR 864.1860510(k) required1 decision since 20000 recalls

1 FDA decision since 2000. No recall names this code.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, pathology panel

Twenty years of NBK at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · NBK

FDA has decided no NBK device since 2007.

Median 510(k) review, days · NBK

Too few NBK 510(k)s in any year since 2007 to give a median.

Recalls per year · NBK

No recall names NBK since 2007.

Adverse event reports per year · NBK

1in 2021

2017: 42021: 1
2007high 4 (2017) · low 0 (2007)2025

MAUDE reports naming product code NBK, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—04
20180—00
20190—00
20200—00
20210—01
20220—00
20230—00
20240—00
20250—00
20260—0—
FIG. 1 — NBK by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in NBK? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Related product codes

Other codes under 21 CFR 864.1860.